Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Acorda Therapeutics Inc (NASDAQ:ACOR)

25.39
Delayed Data
As of 3:55pm ET
 +0.08 / +0.32%
Today’s Change
23.85
Today|||52-Week Range
43.63
-40.65%
Year-to-Date
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Jun 23 / Zacks.com - Paid Partner Content
7 Biotech Stocks that are Buys Right Now
Jun 17 / Zacks.com - Paid Partner Content
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Jun 21 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close25.31
Today’s open25.75
Day’s range24.92 - 25.95
Volume366,641
Average volume (3 months)734,477
Market cap$1.2B
Dividend yield--
Data as of 3:55pm ET, 06/29/2016

Growth & Valuation

Earnings growth (last year)-40.48%
Earnings growth (this year)-28.85%
Earnings growth (next 5 years)+29.00%
Revenue growth (last year)+22.71%
P/E ratio82.6
Price/Sales3.79
Price/Book1.80

Competitors

 Today’s
change
Today’s
% change
INVAInnoviva Inc+0.46+4.47%
EBSEmergent BioSolution...-0.17-0.60%
ALDRAlder Biopharmaceuti...+0.18+0.75%
PRTAProthena Corporation...+0.62+1.70%
Data as of 3:55pm ET, 06/29/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$0.20
Annual revenue (last year)$492.7M
Annual profit (last year)$11.1M
Net profit margin2.24%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Ronald Cohen
Head-
Business Operations
David Lawrence
Corporate headquarters
Ardsley, New York

Forecasts

Partner Offers

Search for Jobs